Pembrolizumab-Induced Hypothyroidism: A Case Report

Pembrolizumab is a monoclonal antibody frequently used as immunotherapy for lung cell carcinoma that has been reported to cause hypothyroidism and myasthenia gravis among other, unwanted side effects. Here, we present an interesting case of a 77-year-old male previously diagnosed with lung adenocarc...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaibor, Carlos, Das, Rohan, Reddy, Vijayakumari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Endocrinology/Diabetes/Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348603/
https://www.ncbi.nlm.nih.gov/pubmed/37457610
http://dx.doi.org/10.7759/cureus.41889
_version_ 1785073701930139648
author Gaibor, Carlos
Das, Rohan
Reddy, Vijayakumari
author_facet Gaibor, Carlos
Das, Rohan
Reddy, Vijayakumari
author_sort Gaibor, Carlos
collection PubMed
description Pembrolizumab is a monoclonal antibody frequently used as immunotherapy for lung cell carcinoma that has been reported to cause hypothyroidism and myasthenia gravis among other, unwanted side effects. Here, we present an interesting case of a 77-year-old male previously diagnosed with lung adenocarcinoma managed with pembrolizumab. Initially, he was admitted after a mechanical fall sustaining a facial laceration and subacute fracture in the nasal bone. However, during the workup, thyroid-stimulating hormone (TSH) was found to be elevated, which was attributed to the history of pembrolizumab usage.
format Online
Article
Text
id pubmed-10348603
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-103486032023-07-15 Pembrolizumab-Induced Hypothyroidism: A Case Report Gaibor, Carlos Das, Rohan Reddy, Vijayakumari Cureus Endocrinology/Diabetes/Metabolism Pembrolizumab is a monoclonal antibody frequently used as immunotherapy for lung cell carcinoma that has been reported to cause hypothyroidism and myasthenia gravis among other, unwanted side effects. Here, we present an interesting case of a 77-year-old male previously diagnosed with lung adenocarcinoma managed with pembrolizumab. Initially, he was admitted after a mechanical fall sustaining a facial laceration and subacute fracture in the nasal bone. However, during the workup, thyroid-stimulating hormone (TSH) was found to be elevated, which was attributed to the history of pembrolizumab usage. Cureus 2023-07-14 /pmc/articles/PMC10348603/ /pubmed/37457610 http://dx.doi.org/10.7759/cureus.41889 Text en Copyright © 2023, Gaibor et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Endocrinology/Diabetes/Metabolism
Gaibor, Carlos
Das, Rohan
Reddy, Vijayakumari
Pembrolizumab-Induced Hypothyroidism: A Case Report
title Pembrolizumab-Induced Hypothyroidism: A Case Report
title_full Pembrolizumab-Induced Hypothyroidism: A Case Report
title_fullStr Pembrolizumab-Induced Hypothyroidism: A Case Report
title_full_unstemmed Pembrolizumab-Induced Hypothyroidism: A Case Report
title_short Pembrolizumab-Induced Hypothyroidism: A Case Report
title_sort pembrolizumab-induced hypothyroidism: a case report
topic Endocrinology/Diabetes/Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348603/
https://www.ncbi.nlm.nih.gov/pubmed/37457610
http://dx.doi.org/10.7759/cureus.41889
work_keys_str_mv AT gaiborcarlos pembrolizumabinducedhypothyroidismacasereport
AT dasrohan pembrolizumabinducedhypothyroidismacasereport
AT reddyvijayakumari pembrolizumabinducedhypothyroidismacasereport

Ejemplares similares